Emerging Infectious Disease Diagnostics: Markets and Trends

Emerging Infectious Disease Diagnostics: Markets and Trends

Why is it important to examine the world of emerging infectious diseases? In a 2015 TED Talk, Microsoft creator Bill Gates warned that there was a lack of preparation for a viral epidemic. He predicted that it would be “microbes, not missiles” that would cause significant harm to humans. Events in recent years have proven him right. Outbreaks of infections such as Zika and Ebola, the MERS threat, the SARS outbreak, the threat of TB and influenza epidemics, and HIV and STD’s uncontrolled march across continents have shown healthcare professionals that one can never remain complacent. Viral and bacterial pathogens are like a cat; they always come back and sometimes with more vigor than expected.

In light of the COVID-19 (coronavirus) pandemic that was announced March 11, 2020, it is extremely timely to present a review of the status quo in emerging infectious diseases. While the current pandemic is troublesome and has disrupted normal life, it will follow its course and then fade away.

In a weird twist of fate, the crisis in emerging infectious diseases is bringing the plight of the developing world to the attention of richer countries and world health organizations. Tests designed for developing countries are gaining in perceived value because they fulfill a huge need there, but also because they can be used to address the need of decentralized testing in resource poor areas in developed countries.

Thus not only is it imperative to have rapid and efficient tests for countries in the developing world, healthcare providers in developed countries can also benefit. The situation in developed countries is probably less urgent for the tropical diseases, but it is equally important to have better rapid tests for hepatitis, HIV, tuberculosis, and sexually transmissible diseases worldwide. To bolster developing countries' public health efforts, private and public funds are pouring dollars in to stem the tide of diseases such as HIV, tuberculosis, malaria, sexually transmissible diseases, and others.

Emerging Infectious Disease Diagnostics: Markets and Trends from Kalorama Information provides then an important addition to business planning to supplement infectious disease market research on known infectious diseases. As seen with the COVID-19 pandemic, business modeling based on current diseases alone would not capture the entire opportunity. Real-world estimates are of known threats, but as these estimates can only reflect current markets, the report also provides outlook assessments and analyzes the opportunity for emerging infections testing.

The report provides the following market information:

• Markets for Emerging Infectious Diseases (Malaria, Lyme Disease, Chagas, Chikungunya, West Nile, Dengue Fever, Ebola, Zika, Others), 2019 and 2023 ($million)
• Most Probable Threats, presenting the most known but yet still emerging diseases currently facing the healthcare systems of developing and increasingly developed nations
• Current Diagnostic Tests for Emerging Diseases
• Companies That Produce Emerging Disease Tests
Companies profiled in the report include:
• altona Diagnostics
• Arkray
• Atomo Diagnostics
• Bioneer
• Chembio Diagnostics, Inc.
• Coris BioConcept
• CTK Biotech, Inc.
• Luminex
• MBio Diagnostics, Inc.
• QIAGEN N.V.
• Quest Diagnostics
• Rheonix, Inc.
• Thermo Fisher Scientific Inc.
• Vela Diagnostics